Marisa Wexler, MS, senior science writer —

Treatment with a high dose of ILB, an experimental injection therapy being developed by Tikomed, was well tolerated and appeared to slow the progression of amyotrophic lateral sclerosis (ALS) in a small clinical trial in the U.K. That’s according to data from the exploratory Phase 2 study…

In amyotrophic lateral sclerosis (ALS), nerve cells in the spinal cord responsible for inhibiting motor neurons are lost in the early stages of the disease, before the motor neurons themselves, according to a new study done in a genetic mouse model of ALS. The researchers also found that excitatory…

After up to 3.5 years on the experimental oral treatment CNM-Au8, the chances of survival for people with amyotrophic lateral sclerosis (ALS) in the open-label extension of the HEALEY ALS platform trial was nearly 60% higher than for a group of patients given a placebo in previous studies.

The U.S. Department of Defense (DoD) has awarded more than $2 million to help Pathmaker Neurosystems conduct a second clinical trial of its MyoRegulator — an experimental, noninvasive nerve modulating device — in people with amyotrophic lateral sclerosis (ALS). “We are very pleased to have…

The European Commission has approved Qalsody (tofersen) as a treatment for amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene, known as SOD1-ALS. Qalsody was specifically granted marketing authorization under exceptional circumstances — a pathway recommended when the benefit-to-risk assessment for a therapy is favorable, but…

By taking advantage of a molecular interaction between the disease-related protein TDP-43 and another, innocuous protein, scientists have found a novel strategy that potentially may be used as a treatment for amyotrophic lateral sclerosis (ALS). “Importantly, this interaction could be key to unlocking a treatment not just for ALS…

Scientists at Broken String Biosciences and the Francis Crick Institute are teaming up to study how genomic instability, or an increased tendency to DNA mutations, contributes to amyotrophic lateral sclerosis (ALS). The findings may shed light on the mechanisms leading to sporadic cases of ALS, the term…

Troriluzole, a new formulation of the approved amyotrophic lateral sclerosis (ALS) treatment riluzole, can be taken with or without food and appears to have better pharmacological properties than approved versions of the medication that allow once daily administration. That’s according to data from three studies in healthy volunteers presented…

Stem cell therapy, specifically treatment with mesenchymal stem cells or MSCs, did not substantially alter disease progression among people with amyotrophic lateral sclerosis (ALS), according to new data from a Phase 2 clinical trial. However, there was a subset of patients who did appear to experience notable benefits from…

In people who experience a traumatic brain injury, or TBI — which is linked to a greater likelihood of developing amyotrophic lateral sclerosis (ALS) — blocking the activity of a protein called KCNJ2 may lower the risk of ALS, according to new research done in lab models. “Targeting KCNJ2…